Moderna Inc. ($MRNA) Stock Forecast: Down 5.4% Today

What is Moderna Inc.?

Moderna, Inc. ($MRNA) is a pharmaceutical company recognized for its development of mRNA-based vaccines, notably a widely-used COVID-19 vaccine. The company has been a leader in vaccine innovation and has faced notable market fluctuations recently.

Why is Moderna Inc. going down?

MRNA stock is down 5.4% on Mar 9, 2026 15:40

• Sienna Gestion and Quantbot Technologies LP both made significant reductions in their stakes in Moderna, Inc., indicating a lack of confidence in the company's future performance.
• Concerns about Moderna's cash burn post a costly patent settlement and insider selling have led to a cautious outlook among analysts, resulting in a "Reduce" rating and a reduced average price target.
• While the bullish options flow and the resolution of legal issues have generated some positive sentiment, uncertainty regarding regulations and the financial repercussions of the settlement are dampening the stock's performance.
• In summary, today's downward trend in Moderna's stock can be attributed to a mix of decreased investor confidence, financial issues, and regulatory uncertainties stemming from the recent patent settlement.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Sienna Gestion Sells 9,627 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Sienna Gestion significantly reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 95.1%, selling 9,627 shares and retaining 495 shares valued at $254,000. Despite this sell-off, analysts maintain a "Moderate Buy" rating for REGN with an average price target of $802.27, following a recent earnings beat and dividend increase. Insiders, however, have also sold shares totaling $4.14 million over the last 90 days.

https://www.marketbeat.com/instant-alerts/filing-sienna-gestion-sells-9627-shares-of-regeneron-pharmaceuticals-inc-regn-2026-03-09/

Altimmune CEO Durso buys $70,790 in shares

Altimmune, Inc. CEO Jerome Benedict Durso recently purchased 20,000 shares of the company's common stock for $70,790. This comes after a 15% decline in the stock's price over the past week and follows a disappointing Q4 2025 earnings report where the company missed EPS and revenue expectations. Analysts have maintained a "Market Perform" rating due to the lack of clear clinical differentiation for its lead drug candidate in a competitive market.

https://m.investing.com/news/insider-trading-news/altimmune-ceo-durso-buys-70790-in-shares-93CH-4549448?ampMode=1

Lyme Disease Vaccine Market Is Booming So Rapidly | Valneva SE • Pfizer Inc. • Moderna Inc

A new report by Coherent Market Insights projects substantial growth for the United States Lyme Disease Vaccine Market from 2026 to 2033, driven by increasing strategic initiatives from major players like Valneva SE, Pfizer Inc., and Moderna Inc. The report offers a comprehensive analysis of market trends, drivers, challenges, and the competitive landscape, providing insights for businesses to make informed decisions. It covers segmentation across product types, applications, end-users, and geographies, along with financial performance and strategies of leading companies.

https://www.openpr.com/news/4416866/lyme-disease-vaccine-market-is-booming-so-rapidly-valneva-se

Quantbot Technologies LP Sells 34,481 Shares of Moderna, Inc. $MRNA

Quantbot Technologies LP significantly reduced its stake in Moderna, Inc. by 58.6% in the third quarter, selling 34,481 shares and retaining 24,373 shares valued at approximately $630,000. This divestment comes amidst concerns about Moderna's cash burn following a patent settlement costing up to $2.25 billion, alongside considerable insider selling and a cautious "Reduce" rating from analysts with an average price target of $32.33. The article highlights both positive sentiments like the removal of a legal overhang and bullish options flow, as well as negative factors such as regulatory uncertainty and the financial impact of the settlement.

https://www.marketbeat.com/instant-alerts/filing-quantbot-technologies-lp-sells-34481-shares-of-moderna-inc-mrna-2026-03-09/

GSK PLC Sponsored ADR $GSK Shares Sold by Quantbot Technologies LP

Quantbot Technologies LP significantly reduced its stake in GSK PLC Sponsored ADR (NYSE:GSK) by 83.2% in the third quarter, selling over 115,000 shares. Meanwhile, major shareholder "Plc Gsk" increased its direct holdings by purchasing 1.47 million shares for approximately $27.93 million. GSK also announced an increased quarterly dividend of $0.4856, marking a 3.6% annualized yield.

https://www.marketbeat.com/instant-alerts/filing-gsk-plc-sponsored-adr-gsk-shares-sold-by-quantbot-technologies-lp-2026-03-07/

Trending Today

American Eagle Outfitters Inc. ($AEO) Stock Forecast: Up 6.6% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 6.3% Today

Macy's Inc ($M) Stock Forecast: Up 5.5% Today

Alaska Air Group Inc. ($ALK) Stock Forecast: Up 6.3% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Up 5.9% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 5.2% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 6.7% Today

CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 5.6% Today

SiteOne Landscape Supply Inc. ($SITE) Stock Forecast: Up 5.6% Today

American Airlines Group Inc. ($AAL) Stock Forecast: Up 5.4% Today

Moderna Inc. Price History

02.02.2026 - MRNA Stock was up 5.2%

• Moderna's stock saw an upward trajectory after receiving endorsement from the CHMP for its mCombriax COVID-19 and influenza combination vaccine. This favorable development, supported by promising Phase III study results, signifies a significant stride towards approval in the EU and potentially beyond.
• A price target increase by Piper Sandler for Moderna mirrors confidence in the company's vaccine portfolio, which includes upcoming milestones like the PDUFA date for the flu vaccine and Phase III melanoma data. Investors are reacting positively to the growth opportunities highlighted by Piper Sandler, despite ongoing safety concerns linked to mRNA technology.
• The positive trend in Moderna's stock stands in contrast to the challenges being tackled by other biotech firms such as Annovis Bio, CRISPR Therapeutics, and Alnylam Pharmaceuticals, as each navigates its distinct developments and regulatory environments.
• In summary, Moderna's bullish movement today is a result of favorable regulatory endorsements, advancements in its pipeline, and market enthusiasm surrounding its vaccine technologies, despite lingering safety considerations.

02.02.2026 - MRNA Stock was up 5.6%

• Moderna's stock rose after receiving a favorable opinion from the European Medicines Agency's drug review committee for its dual Covid-flu vaccine. This places Moderna at the forefront of the global competition for a combined vaccine.
• Concerns expressed by Pfizer's CEO regarding FDA leadership and internal disagreements on vaccine strategies may have indirectly benefitted Moderna, highlighting potential regulatory advantages for the company.
• Analysts have a positive view on Moderna's stock, increasing price targets and emphasizing its robust vaccine pipeline, contributing to investor confidence and the stock's upward movement.
• Moderna's strategic shift towards cancer and rare disease pipelines, in addition to potential regulatory approvals across various regions, showcases the company's diversification beyond Covid-19 vaccines, making it an appealing option for investors.

04.02.2026 - MRNA Stock was up 7.6%

• Following the announcement of a $950 million settlement to resolve patent infringement claims with Arbutus Biopharma Corp and Genevant Sciences GmbH, Moderna's stock saw a notable bullish trend.
• This settlement eliminated a significant financial risk for Moderna, increasing investor confidence in the company's future.
• Despite the substantial settlement, investors interpreted this news positively for Moderna, resulting in the bullish market movement.
• The information about the settlement overshadowed insider sales at Axsome Therapeutics and routine equity compensation activities at Molson Coors Beverage Co, underscoring the impact of legal resolutions on market sentiment.

04.02.2026 - MRNA Stock was up 13.4%

• Moderna's stock saw a notable rise following the resolution of patent disputes with Arbutus and Roivant, resulting in a settlement of up to $2.25 billion. This development brought clarity to Moderna's mRNA pipeline and eliminated a substantial financial risk.
• The settlement news generated optimism among investors regarding Moderna's forthcoming product innovations and potential revenue sources.
• Investor sentiment was positively influenced by the resolution of the legal issues, underscoring the importance of Moderna's capacity for innovation and product launches in sustaining long-term growth and success.

05.02.2026 - MRNA Stock was down 5.5%

• Moderna experienced a bearish movement possibly due to the settlement it reached with Roivant Sciences and Arbutus Biopharma, which involved significant payouts, impacting its financials negatively.
• The positive news of being a top leader among stocks on Wednesday might have been overshadowed by the impact of the settlements on Moderna's finances.
• The increase in headcount by some Massachusetts biotech companies, including Moderna, in 2025, could indicate potential operational expansions that might have been affected by the recent legal settlements.

24.01.2026 - MRNA Stock was down 6.5%

• The bearish movement in MRNA's stock today is linked to concerns over potential FDA actions on mRNA vaccines, causing uncertainty and regulatory hurdles for the company's future vaccine developments.
• The negative revenue outlook and financial challenges may have led to investor caution and selling pressure on the stock.
• Despite recent positive updates, such as regulatory approvals and strategic agreements, the market sentiment appears to have been influenced more by broader challenges and uncertainties facing Moderna, resulting in the bearish movement in the stock today.

05.02.2026 - MRNA Stock was up 7.7%

• Moderna's recent positive developments include a substantial $2.25 billion settlement with Roivant Sciences, resolving patent disputes on lipid nanoparticle technology in COVID-19 vaccines. This settlement not only removes a legal overhang but also shows the company's ability to protect its intellectual property rights effectively.
• Another significant development is Moderna's $950 million settlement with Arbutus Biopharma, providing clarity and resolution on a patent infringement lawsuit related to its Covid-19 vaccine, Spikevax.
• The company's decision to add workers in 2025 amidst industry-wide layoffs suggests strategic growth plans and commitment to expanding its workforce to support research and development efforts, potentially boosting investor confidence in the stock.
• These settlements, coupled with workforce expansion and positive industry developments, may have contributed to investor optimism in Moderna, driving its strong bullish movement in the market.

25.01.2026 - MRNA Stock was up 5.6%

• Despite concerns about Moderna's financial standing, the stock has shown a notable recovery in its share price, signaling growing investor confidence.
• Positive outlook in the options market for Moderna, evident by the majority of trades predicting favorable outcomes, aligns with the current upward trend of the stock.
• Moderna's recent announcement about the FDA's review of its new mRNA flu vaccine, following dispute resolutions, likely contributed to the optimistic market sentiment and stock price surge.
• Protalix Biotherapeutics' strong performance, reaching a new 52-week high, reflects the overall robustness in the pharmaceuticals and biotechnology sector, potentially bolstering investor trust in companies like Moderna.

06.02.2026 - MRNA Stock was down 10.0%

• Moderna's bearish movement today could be attributed to profit-taking by investors after a period of strong gains or concerns about the company's future growth prospects.
• The news about PepGen's muscular dystrophy drug facing FDA hold may have negatively impacted Moderna, as it highlights the regulatory challenges and uncertainties in the biotech industry.
• Additionally, the wider loss and revenue miss by D-Wave Quantum could have spooked investors in the biotech sector, leading to a broader sell-off that affected Moderna's stock price.
• Overall, the combination of regulatory hurdles, financial performance of related companies, and profit-taking behavior likely contributed to Moderna's bearish movement today.

09.02.2026 - MRNA Stock was down 5.4%

• Sienna Gestion and Quantbot Technologies LP both made significant reductions in their stakes in Moderna, Inc., indicating a lack of confidence in the company's future performance.
• Concerns about Moderna's cash burn post a costly patent settlement and insider selling have led to a cautious outlook among analysts, resulting in a "Reduce" rating and a reduced average price target.
• While the bullish options flow and the resolution of legal issues have generated some positive sentiment, uncertainty regarding regulations and the financial repercussions of the settlement are dampening the stock's performance.
• In summary, today's downward trend in Moderna's stock can be attributed to a mix of decreased investor confidence, financial issues, and regulatory uncertainties stemming from the recent patent settlement.

03.02.2026 - MRNA Stock was down 6.2%

• The decline in Moderna's stock today is possibly due to investors taking profits following a period of successful performance.
• Merck's notable revenue growth fueled by Keytruda, a competitor PD-1 inhibitor, might have sparked concerns about potential competition for Moderna in the immuno-oncology sector.
• The proposed stock offering by MAIA Biotechnology to finance trials could have affected Moderna's stock price, as investors may be wary of potential dilution in the biotech industry.
• Despite optimistic outlooks from analysts and advancements in its pipeline, general market sentiment regarding regulatory approvals and market acceptance of Moderna's mRNA-based vaccines may be influencing the stock's movements.

03.02.2026 - MRNA Stock was down 6.3%

• Analysts are bullish on Moderna, maintaining Buy ratings and positive price targets, indicating long-term growth potential.
• The transition to a more diversified business model, including RSV and flu vaccines, has garnered investor interest, but concerns remain regarding regulatory approvals and market adoption.
• The decline in Moderna's stock price could be attributed to the negative market reaction to MAIA Biotechnology's stock sale announcement, raising concerns about potential dilution for existing shareholders.
• Despite positive news of Moderna's dual Covid-flu vaccine nearing EMA approval, regulatory hurdles in the US for other vaccines and shifting focus to different pipelines may have contributed to the bearish market movement.